JP2017533207A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533207A5
JP2017533207A5 JP2017522170A JP2017522170A JP2017533207A5 JP 2017533207 A5 JP2017533207 A5 JP 2017533207A5 JP 2017522170 A JP2017522170 A JP 2017522170A JP 2017522170 A JP2017522170 A JP 2017522170A JP 2017533207 A5 JP2017533207 A5 JP 2017533207A5
Authority
JP
Japan
Prior art keywords
slamf1
antibody
activated
cells
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017522170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056714 external-priority patent/WO2016065038A1/en
Publication of JP2017533207A publication Critical patent/JP2017533207A/ja
Publication of JP2017533207A5 publication Critical patent/JP2017533207A5/ja
Pending legal-status Critical Current

Links

JP2017522170A 2014-10-23 2015-10-21 Slamf1アンタゴニスト及びその使用 Pending JP2017533207A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462067638P 2014-10-23 2014-10-23
US62/067,638 2014-10-23
US201562155810P 2015-05-01 2015-05-01
US62/155,810 2015-05-01
PCT/US2015/056714 WO2016065038A1 (en) 2014-10-23 2015-10-21 Slamf1 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2017533207A JP2017533207A (ja) 2017-11-09
JP2017533207A5 true JP2017533207A5 (cg-RX-API-DMAC7.html) 2018-11-29

Family

ID=54397011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522170A Pending JP2017533207A (ja) 2014-10-23 2015-10-21 Slamf1アンタゴニスト及びその使用

Country Status (5)

Country Link
US (1) US20180016555A1 (cg-RX-API-DMAC7.html)
EP (1) EP3209688A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017533207A (cg-RX-API-DMAC7.html)
CN (1) CN108064166A (cg-RX-API-DMAC7.html)
WO (1) WO2016065038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
IL257110B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
EP4516809A3 (en) * 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗pdl1抗体、およびその使用方法
WO2019184909A1 (zh) * 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
BR112021024997A2 (pt) * 2019-07-03 2022-01-25 Oxford Biotherapeutics Ltd Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
PE20230839A1 (es) 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
CN113899903B (zh) * 2020-07-06 2025-08-29 上海市免疫学研究所 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用
CN116284405B (zh) * 2023-03-15 2024-03-19 中国科学技术大学 靶向cd150蛋白的纳米抗体及其应用
CN116162653A (zh) * 2023-03-30 2023-05-26 湖北省农业科学院畜牧兽医研究所 靶向切除猪SlamF1基因编码区DNA的成对编辑位点、使用方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576423A (en) * 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
CA2206610A1 (en) * 1994-12-02 1996-06-06 Schering Corporation Purified genes encoding mammalian cell surface antigens; proteins and antibodies
WO2004024097A2 (en) * 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2012121429A1 (ko) * 2011-03-07 2012-09-13 연세대학교 산학협력단 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커

Similar Documents

Publication Publication Date Title
JP2017533207A5 (cg-RX-API-DMAC7.html)
JP2018512430A5 (cg-RX-API-DMAC7.html)
Ward-Kavanagh et al. The TNF receptor superfamily in co-stimulating and co-inhibitory responses
Buchan et al. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Mahoney et al. Combination cancer immunotherapy and new immunomodulatory targets
Pasero et al. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
JP2019528082A5 (cg-RX-API-DMAC7.html)
Lu OX40 and OX40L interaction in cancer
Ando et al. Concanavalin A-mediated T cell proliferation is regulated by herpes virus entry mediator costimulatory molecule
CN113260368A (zh) 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途
JP7240808B2 (ja) Psgl-1モジュレーターおよびその使用
JP2020500010A5 (cg-RX-API-DMAC7.html)
WO2016126781A4 (en) Tnfrsf-binding agents and uses thereof
US11939367B2 (en) BTLA fusion protein agonists and uses thereof
JP2022058725A (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
Patel et al. Prominent targets for cancer care: immunotherapy perspective
Chowdhury et al. Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial
Ababneh et al. Tumor necrosis factor superfamily signaling: life and death in cancer
Schreiner et al. Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo
Ritu et al. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics
Ye et al. Immune checkpoint blockade for cancer therapy: current progress and perspectives
Huang et al. The breakthroughs in cancer immune checkpoint based therapy: a review of development in immune checkpoint study and its application
HRP20210383T1 (hr) Kombinirana terapija za rak
Duhen et al. AGONISTIC ANTIBODIES IN CANCER IMMUNOTHERAPY
Kornbluth et al. Multimeric Soluble 4-1BBL as a T Cell Stimulator for Adoptive Immunotherapy.